Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for RYTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 68.82M
March 31, 2026 68.45M
December 31, 2025 67.21M
September 30, 2025 66.68M
June 30, 2025 63.91M
March 31, 2025 63.49M
December 31, 2024 62.39M
September 30, 2024 61.44M
June 30, 2024 61.10M
March 31, 2024 60.96M
December 31, 2023 59.43M
September 30, 2023 59.09M
June 30, 2023 56.90M
March 31, 2023 56.85M
December 31, 2022 56.61M
September 30, 2022 55.76M
June 30, 2022 50.45M
March 31, 2022 50.39M
December 31, 2021 50.28M
September 30, 2021 50.27M
June 30, 2021 50.23M
March 31, 2021 50.20M
December 31, 2020 44.24M
September 30, 2020 44.20M
June 30, 2020 44.12M
Date Value
March 31, 2020 44.00M
December 31, 2019 44.00M
September 30, 2019 34.58M
June 30, 2019 34.50M
March 31, 2019 34.43M
December 31, 2018 34.41M
September 30, 2018 34.38M
June 30, 2018 34.17M
March 31, 2018 27.28M
December 31, 2017 27.28M
September 30, 2017 1.770M
June 30, 2017 27.13M
March 31, 2017 27.13M
September 30, 2016 27.28M
June 30, 2016 27.13M
March 31, 2016 27.13M
December 31, 2015 27.13M
September 30, 2015 27.13M
December 31, 2014 27.13M
September 30, 2014 27.13M
June 30, 2014 156.94M
March 31, 2014 156.94M
June 30, 2013 156.94M
March 31, 2013 156.94M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
BioMarin Pharmaceutical, Inc. 193.54M
Cytokinetics, Inc. 138.76M
Exelixis, Inc. 248.88M